The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • eHealth software provider Respiri (RSH) has completed a share purchase plan (SPP) to raise $3.14 million
  • Originally, Respiri sought to raise $1 million, however, due to strong support the capacity was increased to $3.14 million
  • More than 57 million shares will be issued for 5.5 cents each
  • The SPP follows a private placement completed in March that raised $2 million, bringing the total capital raised in recent months to $5.1 million
  • Respiri says that it is now well capitalised for the commercial launch of its asthma management Wheezo device and platform planned for later this year
  • Company shares are down 1.43 per cent and trading for 6.9 cents each

eHealth software provider Respiri (RSH) has completed a share purchase plan (SPP) to raise $3.14 million.

Originally, Respiri sought to raise $1 million and had the capacity to accept subscriptions up to $2 million. However, due to strong support, the board increased the SPP capacity to raise up to $3.14 million.

This has now been completed and more than 57 million shares will be issued for 5.5 cents each.

The SPP follows a private placement in March that raised $2 million and brings the total capital raised in recent months to $5.1 million.

Respiri said that it is now well capitalised for the commercial launch of its asthma management Wheezo device and platform planned for later this year.

Specifically, when initially announcing the SPP, the company said that funds from the SPP and placement would be used for product and clinical development, manufacturing, sales and marketing of Wheezo.

Company shares are down 1.43 per cent and trading for 6.9 cents each at 2:27 pm AEST.

RSH by the numbers
More From The Market Online
advanced mri or ct scan medical diagnosis machine at hospital lab

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Imricor Medical Systems Ltd intends to use the capital raising's funds to support a three-pronged growth…
Abstract visualization of a brain hemorrhage from an MRI perspective, with vivid colors marking the hemorrhagic areas against the brain's grayscale anatomy.

Trial for Alterity’s neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results…
The Market Online Video

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Recce Pharmaceuticals Ltd has been funded to the tune of US$2M by the US Department of…
AI gen cancer cell

Immutep reports strong response rate from immunotherapies treating carcinomas

Immutep Ltd has reported a slew of positive results from a trial to assess a combination…